INPP5E Signaling and Treatment in Rheumatoid Arthritis
Funded at University of Pennsylvania · NIH-11393647 · Data updated 2026-11-12
This project explores how a specific molecule, INPP5E, affects inflammation in rheumatoid arthritis and whether it could become a new treatment option.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 18, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $528,302 |
| NIH project number | 5R01AR084491-03 |
| Project ID | NIH-11393647 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with rheumatoid arthritis, particularly those who have inadequate response to current DMARDs or biologic therapies.
✕Less likely to help
Patients with RA who are not eligible for research procedures or have contraindications to study interventions may not benefit.
What this research studies
If successful, this study will look at how INPP5E controls immune cell behavior in the joints of people with RA and how it interacts with known inflammatory pathways. Researchers will analyze human synovial tissue data and mouse models to understand how INPP5E loss or gain affects inflammation and bone damage. The work aims to identify drug targets that could modulate the immune response and reduce joint destruction in RA patients.
Why it matters
Potential benefit: If successful, the research could lead to new therapies that better control inflammation and prevent joint damage in RA.
How similar studies have gone: Preliminary data in animal models and human data suggest INPP5E is linked to inflammatory signaling and could be a viable drug target, but human proof of concept is still needed.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Yang, Shuying — University of Pennsylvania
- Study coordinator: Yang, Shuying
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Role of Stabilin receptors in rheumatoid arthritis
A short study to understand how certain scavenger receptors may influence the development and progression of rheumatoid arthritis in adults.
-
IgG glycosylation and endothelial FcγRIIB: understanding RA-related heart and blood vessel disease
This project looks at how rheumatoid arthritis affects blood vessels and clotting, with the goal of uncovering new ways to prevent heart and stroke risk for people with RA.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Pregnancy changes in rheumatoid arthritis and new treatment ideas
This research seeks to understand why some women’s rheumatoid arthritis improves during pregnancy and how to predict and mimic that effect to make treatments safer and more effective for pregnant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.